First Quadrant’s Apyx Medical APYX Stock Holding History

First Quadrant’s Portfolio APYX Stock Details APYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,800	Closed	-$62K	–	166
2021 Q4	$62K	Buy	+4,800	New	+$67.1K	0.01%	391

Other funds holding APYX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Quadrant's APYX Position: Q1 2022 in Review

First Quadrant sold out of Apyx Medical (APYX) in Q1 2022, closing a stake of 4,800 shares — an estimated $62K sold.

First Quadrant first reported a position in APYX in Q4 2021 and held it in 1 quarter. The position peaked at $62K in Q4 2021. 71 funds tracked by Wall St. Rank hold APYX as of Q1 2022.

First Quadrant reported no remaining Apyx Medical position as of Q1 2022 after selling out during the quarter.
First Quadrant sold 4,800 Apyx Medical shares in Q1 2022, an estimated $62K.
First Quadrant first reported a position in Apyx Medical in Q4 2021 and held it in 1 quarter.
First Quadrant's Apyx Medical position peaked at $62K in Q4 2021.
71 funds tracked by Wall St. Rank held Apyx Medical as of Q1 2022.

Based on First Quadrant's 13F filing for Q1 2022, filed 21 Apr 2022.